

BOLDENONE UNDECYLENATE

BOLDENONE UNDECYLENATE USP 250mg Oil Base q.s. Presented as 10 x 1ml ampoules per box (250mg/ml)

DESCRIPTION

BOLDENONE UNDECYLENATE is an injectable anabolic preparation. After injection, boldenone undecylenate is gradually released from the intramuscular depot and subsequently hydrolyzed into dihydroboldenone.

Boldenone is indicated for Osteoporosis due to androgen deficiency in hypogonadal males. It will also cause the muscle cell to store more nitrogen than it does release so that a positive nitrogen balance is achieved. A positive nitrogen balance is synonymous with anabolism and assimilates a larger amount of protein than usual

Boldenone Undecylenate is a long acting compound, with the undecanoate ester providing this drug a slow release time of up to three weeks

INDICATIONS

Boldenone Undecylenate is approved for the following uses: As an anabolic steroid

Treatment of certain cases of disseminated breast cancer in women Osteoporosis due to androgen deficiency in hypogonadal males

CONTRAINDICATIONS

Not intended for use in children. Known or suspected prostatic carcinoma and mammary carcinoma in the male. Not intended for use in female patients other than those with disseminated breast

Contraindicated in nephrosis or the nephrotic phase of nephritis. cardiac and renal failure, hypercalcaemia, oedema, jaundice, liver disease with impaired bilirubin excretion, testicular and hepatic

DOSAGE AND DIRECTIONS FOR USE

Boldenone Undecylenate injection should be administered by deep intramuscular injection.
Adult dose: 75 mg to 150 mg every three weeks.

SIDE EFFECTS AND SPECIAL PRECAUTIONS

Virilization which appears in sensitive women as hoarseness, acne, hirsutism and increased libido; in prepubertal boys as an increased frequency of erections and phallic enlargement, and in girls as an increase of pubic hair and clitoral hypertrophy. Hoarseness may be the first symptom of vocal change which may end in a long-lasting, sometime irreversible deepening of the voice.

Other adverse reactions may include: Oligospermia and decreased ejaculatory volume. Suppression of

ovarian activity, atrophy of the breasts and endometrial tissue Amenorrhea and inhibition of spermatogenesis. Water and salt

Patients with the following conditions should be monitored: Latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions), since anabolic steroids may induce salt and fluid retention. Diabetes, since anabolic steroids may improve the glucose tolerance and decrease the need for insulin or other antidiabetic

Incomplete stature growth, since anabolic steroids may induce hypercalcemia and hypercalciuria in these patients Liver dysfunction.

DRUG INTERACTIONS

Liver enzyme-inducing agents may reduce the effects of Boldenone by enhancing its effects in the liver.

PRESENTATION

250 mg/ml, 1 x 10 ml ampoules

Store in a cool dry place (30 °C ± 2 °C).

Protect from light.
Warming and rotating the ampoule between the palms of the hands will redissolve any crystals that may have been formed during storage at low temperatures

AURORA REMEDIES, SINGAPORE

www.aurora-remedies.com